The Oncology Institute (TOI) have received certification to begin administering Pluvicto therapy in their outpatient California radiation oncology practices. Pluvicto, a radiopharmaceutical used to treat certain types of metastatic prostate cancer, has previously been administered primarily in hospital settings.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TOI:
- The Oncology Institute joins Lantern’s cancer care network of excellence
- The Oncology Institute, AJMC to co-host symposium for value-based cancer care
- The Oncology Institute announces expansion into Oregon
- Oncology Institute Announces CFO Transition and Strategic Growth Plan
- The Oncology Institute CFO Mihir Shah to depart, Rob Carter to succeed